Avita Medical Ltd ( (RCEL) ) has released its Q3 earnings. Here is a breakdown of the information Avita Medical Ltd presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AVITA Medical Ltd is a therapeutic acute wound care company specializing in innovative solutions for wound healing, primarily operating in the healthcare sector with a focus on the RECELL System for burn and trauma wounds.
In its third-quarter 2025 financial results, AVITA Medical reported a commercial revenue of $17.1 million, marking a 13% decrease compared to the same period in 2024, alongside a reduction in operating expenses by 24% to $23.0 million. The company also improved its net cash usage, highlighting a focus on financial efficiency.
Key financial metrics include a net loss improvement to $13.2 million from $16.2 million in the previous year, with a gross profit margin of 81.3%. The company achieved significant milestones such as CE Mark approval for RECELL GO® in Europe and restored reimbursement clarity in the U.S., which are expected to bolster future revenue streams.
Despite the lowered full-year revenue outlook to $70-$74 million from the previous $76-$81 million guidance, AVITA Medical remains optimistic about its strategic focus on high-value U.S. burn and trauma centers and its potential for growth in the $1.3 billion addressable market.
Looking forward, AVITA Medical aims to enhance its financial flexibility and continue its disciplined growth strategy, with plans to provide updates on capital and growth strategies in early 2026, while maintaining a strong emphasis on cash management and commercial execution.